What Axogen, Inc. does.

We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Drug Administration (“FDA”) on December 3, 2025 for the treatment of adult and pediatric patients aged one month or older with sensory, mixed, and motor peripheral nerve discontinuities (“Avance”) and is expected to be commercially available early in the second quarter of 2026 as a replacement for Avance® Nerve Graft;

• Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site (“Avance Nerve Graft” and together with Avance, the “Avance Products”);

Revenue and profit, by fiscal year.

More on AXGN.

• Axogen, Inc. summary
• Axogen, Inc. financial statements
• Axogen, Inc. key metrics
• Axogen, Inc. health scores and style box
• Axogen, Inc. earnings
• Axogen, Inc. dividends
• Axogen, Inc. valuation
• Axogen, Inc. ownership and insiders
• Axogen, Inc. peers

Figures from Axogen, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.